Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II StudyGATELL, Jose M; KATLAMA, Christine; MEIBOHM, Anne R et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 4, pp 456-463, issn 1525-4135, 8 p.Article

Pharmacokinetics and Safety of Caspofungin in Older Infants and ToddlersNEELY, Michael; JAFRI, Hasan S; STONE, Julie A et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 4, pp 1450-1456, issn 0066-4804, 7 p.Article

Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non-albicans Candida Species: Review of the Caspofungin DatabaseCOLOMBO, Arnaldo L; NGAI, Angela L; BOURQUE, Michael et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 5, pp 1864-1871, issn 0066-4804, 8 p.Article

Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of AgeSAEZ-LLORENS, Xavier; MACIAS, Mercedes; PENG SUN et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 3, pp 869-875, issn 0066-4804, 7 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive CandidiasisBETTS, Robert F; NUCCI, Marcio; STROHMAIER, Kim M et al.Clinical infectious diseases. 2009, Vol 48, Num 12, pp 1676-1684, issn 1058-4838, 9 p.Article

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionMARKOWITZ, Martin; NGUYEN, Bach-Yen; CAMPBELL, Havilland et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 3, pp 350-356, issn 1525-4135, 7 p.Article

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsERON, Joseph J; COOPER, David A; LOUTFY, Mona R et al.Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 587-596, issn 1473-3099, 10 p.Article

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesROCKSTROH, Jürgen K; TEPPLER, Hedy; JING ZHAO et al.AIDS (London). 2011, Vol 25, Num 11, pp 1365-1369, issn 0269-9370, 5 p.Article

SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTSZAOUTIS, Theoklis; LEHRNBECHER, Thomas; BOURQUE, Michael et al.The Pediatric infectious disease journal. 2009, Vol 28, Num 12, pp 1132-1135, issn 0891-3668, 4 p.Article

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)GOTUZZO, Eduardo; MARKOWITZ, Martin; TEPPLER, Hedy et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 73-77, issn 1525-4135, 5 p.Article

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief reportNGAI, Angela L; BOURQUE, Michael R; LUPINACCI, Robert J et al.International journal of antimicrobial agents (Print). 2011, Vol 38, Num 6, pp 540-544, issn 0924-8579, 5 p.Article

A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and NeutropeniaMAERTENS, Johan A; MADERO, Luis; STROHMAIER, Kim M et al.The Pediatric infectious disease journal. 2010, Vol 29, Num 5, pp 415-420, issn 0891-3668, 6 p.Article

A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric PatientsZAOUTIS, Theoklis E; JAFRI, Hasan S; SEIBEL, Nita et al.Pediatrics (Evanston). 2009, Vol 123, Num 3, pp 877-884, issn 0031-4005, 8 p.Article